Integra LifeSciences Holdings Corporation · NASDAQ:IART

Integra LifeSciences — FY2022 Earnings Presentation

24 slides from Integra LifeSciences's earnings presentation, Feb 22, 2023

  1. Slide 1: Q4 & Full Year 2022 Earnings Presentation

    Q4 & FULL YEAR 2022 EARNINGS PRESENTATION FEBRUARY 22, 2023

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of hist

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted net income, adjusted earnings per diluted share, adjusted gross margin, free cas

  4. Slide 4: 2022 Progress on Strategic Priorities

    2022 Progress on Strategic Priorities Advanced Advanced our strategic along path our strategic path Strengthened Strengthened our capabilities our capabilities  Product/market launches  Outsourced and automated select back-office  Extended the CUSA® Clarity portfolio  U.S. launch of NeuraGen® 3D

  5. Slide 5: Q4 & Full Year 2022 Financial Performance

    Q4 & FULL YEAR 2022 FINANCIAL PERFORMANCE

  6. Slide 6: 2022 Full Year Financial Highlights

    2022 Full Year Financial Highlights Revenue & Growth Adj. EPS FY Revenue (in $M) $3.36 +5.7% vs. 2021 $1,558 $1,542 5 $1,5 50.0 4.5 4 $1,5 30.0 3.5 Adj. EBITDA margin 3 $1,5 10.0 2.5 2 $1,4 90.0 1.5 1 $1,4 70.0 26.4% +40bps vs. 2021 0.5 $1,4 50.0 0 FY'21 FY'22 Reported +1.0% vs. 2021 Operating Cash

  7. Slide 7: 2022 Q4 Total Revenue

    2022 Q4 Total Revenue Revenue & Growth Key drivers Q4 Revenue (in $M) • Procedures approaching pre-Covid levels $406 $42 0.0 5 $398 4.5 $41 0.0 • US CSS – Neurosurgery and Instrument demand 4 $40 0.0 3.5 3 recovery, partially offset by supply challenges and $39 0.0 2.5 $38 0.0 2 CereLink recall 1.5

  8. Slide 8: Codman Specialty Surgical Q4 Revenue

    Codman Specialty Surgical Q4 Revenue Revenues Q4’22 Q4’21 Growth Reported $264.6M $270.7M (2.2%) Q4 2022 Organic1 $273.0M $268.2M 1.8% Revenue Composition Q4 2022 Growth and Performance Drivers2 Instruments Neurosurgery Instruments International 22% 1.7% 2.2% Low single-digits • Neurosurgery – Low d

  9. Slide 9: Tissue Technologies Q4 Revenue

    Tissue Technologies Q4 Revenue Revenues Q4’22 Q4’21 Growth Reported1 $133.4M $134.9M (1.1%) Q4 2022 Organic2 $134.0M $127.5M 5.0% Revenue Composition Q4 2022 Growth and Performance Drivers3 Private Wound Reconstruction Private Label International Label 23% 8.2% (4.2%) Low single-digits • Wound Recon

  10. Slide 10: 2022 Q4 and Full Year Financial Results

    2022 Q4 and Full Year Financial Results ($M except per share data) Q4 2022 Full-Year 2022 Adj. Gross Profit Adj. EBITDA Adj. EPS Adj. Gross Profit Adj. EBITDA Adj. EPS (50bps) Margin +160bps Margin +11.9% (50bps) Margin +40bps Margin +5.7% $271.1 $105.4 $109.7 $1,046.4 $3.36 $30 0.0 $264.0 20 120 .0

  11. Slide 11: Balance Sheet and Cash Flow Performance

    Balance Sheet and Cash Flow Performance Operating Cash Flow, Free Cash Flow ($M) & Adj. FCF Conversion (%) Summary Balance Sheet ($M) 12/31/21 12/31/22 FCF Capex 350 $312.4 Cash and Cash Equivalents $513 $457 $48.0 300 $264.5 Total Debt $1,563 $1,455 250 $42.3 $85.3 Net Debt $1,050 $998 90 200 $69.3

  12. Slide 12: 2023 Outlook - Key Drivers

    2023 Outlook - Key Drivers Revenue Growth Strengthened Stepped Up Acceleration Margin Accretion Growth Investments • Procedures near pre- • Favorable product mix • SurgiMend® and DuraSorb COVID levels PMAs • Price capture • Commercial capacity • New products • Manufacturing efficiencies • Gradual su

  13. Slide 13: Full Year 2023 Outlook

    Full Year 2023 Outlook FY 2023 Reported Revenue Guidance Bridge ($M) 1H / 2H Overview ~$9 4.0% - 5.2% $1,602 - $1,620 ~6%* ~($20) ~($6) ~3%* $1,558 1H 2H * Implied 1H and 2H at mid-point of guidance 1H / 2H organic growth profile drivers • Gradual supply recovery • Private Label normalization post 1

  14. Slide 14: Q1 2023 Outlook

    Q1 2023 Outlook Q1 2023 Reported Revenue Guidance Bridge ($M) 2.0% - 3.5% ~$2 $377 ~($8) $370 - $376 ~($8) • Revenue: $370M-$376M • Reported Growth -1.5% to ~flat • Adj EPS $0.72 - $0.76 • Organic Growth +2.0% to +3.5% Q1 Guidance reflects solid demand recovery partially offset by timing items 14 IA

  15. Slide 15: Strategic Pillars - Driving an integrated growth strategy

    Strategic Pillars - Driving an integrated growth strategy Growth Drivers Enablers Innovate for Grow Broaden care Drive operations Cultivate a high- outcomes international pathway and customer performance impact excellence culture 15

  16. Slide 16: Conclusion

    Conclusion  Delivered strong 2022 Financial results while advancing our strategy • Recovering markets and resilient demand for our technologies and strong brands • Exceeded profit commitments through OPEX restructuring and efficiency projects while investing in strategic initiatives and critical ca

  17. Slide 17: Appendix: Non-GAAP Reconciliations

    Appendix Non-GAAP Reconciliations

  18. Slide 18: Fourth Quarter and FY 2022 Financial Results

    Fourth Quarter and FY 2022 Financial Results Note: Numbers may not add due to rounding % of Revenues Q4 2022 Q4 2021 Change FY 2022 FY 2021 Change Total Revenues $398.0 $405.5 (1.8%) $1,557.7 $1,542.4 1.0% Gross Margin 62.8% 61.5% +130BPS 62.3% 61.2% +110BPS Adj. Gross Margin(1) 66.3% 66.8% -50BPS 6

  19. Slide 19: Fourth Quarter and FY 2022 Organic Growth Reconciliation

    Fourth Quarter and FY 2022 Organic Growth Reconciliation Note: Numbers may not add due to rounding (In millions) Q4 2022 Q4 2021 FY 2022 FY 2021 Neurosurgery $205.2 $211.9 $794.0 $803.0 Instruments $59.4 $58.8 $225.5 $222.3 Total Codman Specialty Surgical $264.6 $270.7 $1,019.6 $1,025.2 Wound Recons

  20. Slide 20: Fourth Quarter and FY 2022 Adjusted EBITDA Margin Reconciliation

    Fourth Quarter and FY 2022 Adjusted EBITDA Margin Reconciliation Note: Numbers may not add due to rounding (In millions) Q4 2022 Q4 2021 FY 2022 FY 2021 GAAP Net Income $52.9 $45.4 $180.6 $169.1 Depreciation 9.9 10.4 39.9 39.2 Intangible asset amortization 19.6 20.3 78.3 83.4 Other (income), net (2.

  21. Slide 21: Fourth Quarter and FY 2022 Adjusted EPS Reconciliation

    Fourth Quarter and FY 2022 Adjusted EPS Reconciliation Note: Numbers may not add due to rounding (In millions) Q4 2022 Q4 2021 FY 2022 FY 2021 GAAP Net Income $52.9 $45.4 $180.6 $169.1 Acquisition, divestiture and integration-related charges (1) 0.7 1.9 (18.8) (11.7) Structural optimization charges

  22. Slide 22: Fourth Quarter and FY 2022 Adjusted Free Cash Flow Reconciliation

    Fourth Quarter and FY 2022 Adjusted Free Cash Flow Reconciliation Note: Numbers may not add due to rounding (In millions) Q4 2022 Q4 2021 FY 2022 FY 2021 Net Cash from Operating Activities $85.3 $69.3 $264.5 $312.4 Purchases of Property and Equipment ($14.5) ($27.4) ($42.3) ($48.0) Free Cash Flow $7

  23. Slide 23: Fourth Quarter and FY 2022 Gross Margin Reconciliation

    Fourth Quarter and FY 2022 Gross Margin Reconciliation Note: Numbers may not add due to rounding (In millions) Q4 2022 Q4 2021 FY 2022 FY 2021 Reported Gross Profit $250.1 $249.3 $970.3 $944.6 Structural optimization charges (4.2) 2.6 5.6 9.1 Acquisition, divestiture and integration-related charges

  24. Slide 24: Fourth Quarter and FY 2022 Adjusted SG&A Reconciliation

    Fourth Quarter and FY 2022 Adjusted SG&A Reconciliation Note: Numbers may not add due to rounding (In millions) Q4 2022 Q4 2021 FY 2022 FY 2021 Reported SG&A $151.9 $162.3 $616.3 $637.4 Structural optimization charges 2.7 2.6 17.4 7.8 Acquisition, divestiture and integration-related charges (1) 0.6

Integra LifeSciences Holdings — FY2022 Earnings Presentation on 6ix